HOME > NATIONAL > Article

Text Size

small

medium

large


Japan Starts Final-Stage Trial for iPS Drug for Alzheimer's

Japan Starts Final-Stage Trial for iPS Drug for Alzheimer's

Professor Haruhisa Inoue (center) of Kyoto University's Center for iPS Cell Research and Application
Professor Haruhisa Inoue (center) of Kyoto University's Center for iPS Cell Research and Application

   Kyoto, June 3 (Jiji Press)--A Japanese team said Tuesday that it has started a final-stage clinical trial to administer to patients with familial Alzheimer's disease a drug discovered through induced pluripotent stem, or iPS, cells.
   This is the first final-stage trial conducted in the field of iPS drug discovery, which uses iPS cells to discover new efficacies of new and existing drugs, according to the team.
   The team includes members of Kyoto University's Center for iPS Cell Research and Application, or CiRA, and Towa Pharmaceutical Co., which makes and sells generic drugs.
   Through the trial, which began in May, the team aims to confirm the safety and efficacy of the treatment, in hopes of obtaining regulatory approval.
   In 2017, CiRA professor Haruhisa Inoue and others carried out an investigation to find a compound that reduces amyloid beta, which causes Alzheimer's disease, by using iPS cells.

To read a full story, please click here to find out how to subscribe.

NATIONAL

HEADLINES

POLITICS
Trump Increasingly Irritated by Elon Musk's Criticism of Tax Cut Bill: US Media
ECONOMY
Imperial Hotel Kyoto Unveils Guest Room Interior Ahead of Spring 2026 Opening
SPORTS
MLB: All-Star Fan Voting Begins with Shohei Ohtani, Seiya Suzuki Listed for DH
OTHER
Osaka Expo Organizers Struggle to Combat Swarm of Chironomids Annoying Visitors

AFP-JIJI PRESS NEWS JOURNAL


Photos